The Rationale for Initiating Treatment of Hypercholesterolemia in Young Adulthood Daniel Steinberg Statin Drugs (MB Clearfield, Section Editor) 12 December 2012 Article: 296
Moving Beyond JUPITER: Will Inhibiting Inflammation Reduce Vascular Event Rates? Paul M Ridker Statin Drugs (MB Clearfield, Section Editor) 09 December 2012 Article: 295
Is Atherosclerosis Regression a Realistic Goal of Statin Therapy and What Does That Mean? Mukesh SinghUpdesh Singh Bedi Statin Drugs (MB Clearfield, Section Editor) 19 December 2012 Article: 294
Vitamin D, Calcium, and Atherosclerotic Risk: Evidence from Serum Levels and Supplementation Studies Pamela L. LutseyErin D. Michos Nonstatin Drugs (WB Borden, Section Editor) 13 December 2012 Article: 293
Lipid Effects of Psychiatric Medications Junzo WatanabeYutaro SuzukiToshiyuki Someya Nonstatin Drugs (WB Borden, Section Editor) 09 December 2012 Article: 292
How Do We Improve Patient Compliance and Adherence to Long-Term Statin Therapy? Patricia ManingatBruce R. GordonJan L. Breslow Statin Drugs (MB Clearfield, Section Editor) 09 December 2012 Article: 291
Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD? Willibald HochholzerRobert P. Giugliano Statin Drugs (MB Clearfield, Section Editor) 16 December 2012 Article: 290